Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 13.00p 12.50p 13.50p 13.00p 13.00p 13.00p 0 06:35:19
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -3.6 -4.2 - 12.13

Evgen Pharma Share Discussion Threads

Showing 551 to 574 of 575 messages
Chat Pages: 23  22  21  20  19  18  17  16  15  14  13  12  Older
DateSubjectAuthorDiscuss
24/4/2018
09:32
RNS 24 April 2018: The presentation will also refer to the ongoing Phase II trial of SFX-01 in metastatic breast cancer, which is on track to report an interim read-out in Q2 this year with the final read-out around the year end.
vatnabrekk
12/4/2018
15:49
does this company make any money? -12% since the start of the year.
wwick
12/4/2018
12:02
apparently CEO doing proactive event in may.so H1 results could be early?
moneytree1
10/4/2018
09:28
Inflection point soon with narrowing trade channel, we're set for a break out one way or t'other... an RNS in the next week or so would be useful.
rathean
21/3/2018
14:01
ppl keep selling.
moneytree1
08/3/2018
13:05
Why does this keep falling?
wins73
07/3/2018
12:24
Joined you guys with an initial 45700. Market cap seems way too cheap at £12 million. This could do an N4P once momentum builds.
parob
02/3/2018
12:13
IPO was nearly 40p and broker target is nearly 100p So there's plenty of headroom here and barely off the ground from it's lowest lows. looking at the chart when it gets going it really moves.
saw89
02/3/2018
10:38
More sustained buying, could see 20p again before the results.
rathean
01/3/2018
17:00
From the interim results they said; "Early stage pipeline - In collaboration with the medicinal chemists at the University of Seville we have created a range of novel compounds based upon the sulforaphane core structure. Evgen has in-licensed the Seville intellectual property presenting us with multiple new chemical entities based upon sulforaphane. Screening of a series of such novel, proprietary, sulforaphane analogues is underway at the University of Liverpool and the full dataset will be evaluated during Q1 of calendar year 2018." I see the Uni of Seville have just released some research which may be relevant to this; "NMR study on the stabilization and chiral discrimination of sulforaphane enantiomers and analogues by cyclodextrins" hTTps://www.sciencedirect.com/science/article/pii/S0144861717314285?via%3Dihub Hopefully a step forward in the science.
pdt
01/3/2018
10:20
Yes, there is certainly a pick up in the volume of trades. The Capital Network report above suggested that the interim cancer trial readout may be the trigger for licencing activity before the full results at the end of the year. I think there is growing interest in targeting cancer stem cells. The recent University of Manchester poster on SFX-01 at the Breast Cancer Conference was positive and I see Stephen Franklin was interviewed in a recent Cancer Stem Cell report. Interesting times :)
pdt
01/3/2018
10:10
Q1 screening of cancer cells utilising the Sulforadex technology full data readout due in next 4 weeks see page 3 of report, H1 breast cancer interim phase 2 trial readout positioning ahead of news...could get interesting.gl
moneytree1
01/3/2018
09:00
Nice volume this morning, leaky broker ahead of rns wouldn't surprise me.
rathean
22/2/2018
12:04
http://www.capitalnetwork.com/companies/research/110586/evgen-pharma-plc-harnessing-sulforaphane-s-therapeutic-properties-110586.html
ohisay
30/1/2018
11:19
I think it will slip below the 12p placing price as the placing shares are flipped for a nice profit especially with full trial readout not for another 11 months
lambo222
30/1/2018
09:30
Slipping back to floor support levels, good price to buy in ahead of next RNS.
rathean
15/1/2018
13:09
The Breast Cancer conference has a PDF available on it's website. The poster information is on page 80 hTTp://breastcancerconference.org/wp-content/uploads/2018/01/UK-IBCS-Published-Abstracts.pdf On the same page is a study by AstraZeneca doing a similar study with Progesterone receptor antagonists to inhibit cancer stem cell activity. I would be interested to know how they compare.
pdt
15/1/2018
07:39
More scientific evidence released today by the company supporting their Breast cancer treatment. I think the Hardman report estimated the market for this treatment at $5 billion per annum. Look forward to the interim phase II read out by June this year. Early signs are that it works and increasingly they are providing the science of why it works. Hugely important to breast cancer patients.
pdt
12/1/2018
20:29
Another study showing the effectiveness against cancer stem cells; "Sulforaphane reverses gefitinib tolerance in human lung cancer cells via modulation of sonic hedgehog signaling" hTTps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5738694/ Gefitinib is marketed by Astrazeneca under the trade name Iressa. Currently doing $500m per annum in sales.
pdt
12/1/2018
11:41
Chart suggests we're just off the bottom. Any positive news will see it 25p again.
rathean
05/1/2018
20:35
3.4m shares still need to be declared
dave444
04/1/2018
09:31
Surprised that no holding statements have been declared after fundraising
dave444
13/12/2017
10:16
Agreed #Tilly99, share price discounts huge upside. Great entry point, it'll rise quickly when it goes
rathean
13/12/2017
08:50
Floated at 37p? And only had good news since
tilly99
Chat Pages: 23  22  21  20  19  18  17  16  15  14  13  12  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:33 V: D:20180424 10:31:24